INDV · XBRL financial data
Indivior Pharmaceuticals financial statements, every quarter
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (INDV's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | year only | 299* | 266 | 302 | 314 | 358* | 317 | 343 | 356 |
| Cost of goods and services sold | year only | 48* | 44 | 52 | 83 | 67* | 40 | 50 | 51 |
| Gross profit | year only | 250* | 221 | 250 | 230 | 292* | 277 | 294 | 305 |
| Selling, general and administrative | year only | 175 | 132 | 158 | 155 | 189* | 124 | 122 | 119 |
| Total operating expenses | year only | 205 | 156 | 179 | 187 | — | 139 | 134 | 125 |
| Operating income (loss) | year only | 46 | 66 | 72 | 43 | 81* | 137 | 160 | 180 |
| Interest income | year only | 5* | 4 | 6 | 6 | 6* | 3 | 3 | 4 |
| Interest expense | year only | 13* | 12 | 15 | 12 | 6* | 7 | 2 | 2 |
| Income tax expense (benefit) | year only | 17 | 11 | 44 | (5) | (21)* | 26 | 38 | 45 |
| Net income (loss) | year only | 21 | 47 | 18 | 42 | 102* | 89 | 122 | 137 |
| Earnings per share, basic USD per share | — | — | 0.38 | 0.15 | 0.34 | 0.81* | 0.71 | 1.02 | 1.16 |
| Earnings per share, diluted USD per share | — | — | 0.38 | 0.14 | 0.33 | 0.77* | 0.69 | 0.98 | 1.12 |
| Weighted average shares, basic millions of shares | — | 125* | 124 | 125 | 125 | 126* | 124 | 119 | 118 |
| Weighted average shares, diluted millions of shares | — | 127* | 125 | 126 | 129 | 132* | 129 | 124 | 122 |
| Cost of sales | year only | — | — | — | — | — | — | — | — |
| Gross profit | year only | — | — | — | — | — | — | — | — |
| Research and development | year only | — | — | — | — | — | — | — | — |
| Operating profit (loss) | year only | — | — | — | — | — | — | — | — |
| Profit (loss) | year only | — | — | — | — | — | — | — | — |
Balance sheet
CSVFiscal quarters (INDV's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 316 | 319 | 372 | 510 | 445 | 195 | 175 | 222 | 305 |
| Short-term investments | 94 | 1 | 1 | 0 | 0 | 0 | — | — | — |
| Accounts receivable | 254 | 254 | 243 | 240 | 259 | 253 | 273 | 271 | 273 |
| Inventory | 126 | 178 | 163 | 149 | 155 | 153 | 152 | 150 | 149 |
| Prepaid and other current assets | 52 | 53 | — | — | — | — | — | — | — |
| Total current assets | 1,257 | 839 | 883 | 951 | 922 | 652 | 667 | 725 | 800 |
| Property and equipment, net | 84 | 100 | 104 | 117 | 124 | 144 | 157 | 162 | 175 |
| Right-of-use asset | 40 | 39 | 37 | 35 | 30 | 26 | 22 | 21 | 12 |
| Goodwill | 5 | 2 | — | — | — | 2 | — | — | — |
| Total assets | 1,758 | 1,319 | 1,375 | 1,452 | 1,416 | 1,201 | 1,197 | 1,233 | 1,332 |
| Accounts payable | 39 | 63 | 46 | 50 | 41 | 48 | 35 | 30 | 28 |
| Current portion of long-term debt | 3 | 18 | 18 | 18 | 18 | 29 | 0 | 0 | 488 |
| Total current liabilities | 1,281 | 939 | 1,005 | 1,056 | 965 | 914 | 779 | 868 | 1,301 |
| Long-term debt | 237 | 315 | 311 | 308 | 304 | 290 | 486 | 487 | 0 |
| Lease liability, non-current | 34 | 32 | 30 | 29 | 24 | 22 | 14 | 13 | 6 |
| Total liabilities | 1,942 | 1,668 | 1,660 | 1,709 | 1,623 | 1,300 | 1,341 | 1,441 | 1,392 |
| Accumulated deficit | (288) | (454) | (406) | (388) | (346) | (243) | (280) | (334) | (197) |
| Total stockholders' equity | (184) | (348) | (285) | (257) | (207) | (98) | (144) | (208) | (60) |
| Total liabilities and equity | 1,758 | 1,319 | 1,375 | 1,452 | 1,416 | 1,201 | 1,197 | 1,233 | 1,332 |
| Common shares outstanding (cover page) millions of shares | 137 | 125 | 125 | 125 | 125 | 125 | 122 | 118 | 118 |
| Cash and cash equivalents | 316 | — | — | — | — | — | — | — | — |
| Total current assets | 1,263 | — | — | — | — | — | — | — | — |
| Total assets | 1,954 | — | — | — | — | — | — | — | — |
| Total current liabilities | 1,305 | — | — | — | — | — | — | — | — |
| Total liabilities | 1,954 | — | — | — | — | — | — | — | — |
| Total equity | 0 | — | — | — | — | — | — | — | — |
Cash flows
CSVFiscal quarters (INDV's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | year only | 21 | 47 | 18 | 42 | 102* | 89 | 122 | 137 |
| Stock-based compensation | year only | 6* | 6 | 8* | 7* | 5* | 9 | 11* | 8* |
| Depreciation and amortization | year only | 18* | 5 | 0* | 3* | 2* | 2 | 2* | 1* |
| Net cash from operating activities | year only | (17)* | 75 | 158* | (39)* | (221)* | (9) | 229* | 97* |
| Purchases of property and equipment | year only | 16* | 5 | 17* | 20* | 24* | 20 | 7* | 14* |
| Net cash from investing activities | year only | 8* | (5) | (17)* | (20)* | (24)* | (19) | (8)* | (14)* |
| Proceeds from issuing common stock | year only | 0* | 1 | 0* | 1* | 0* | 0 | 0* | 0* |
| Share repurchases | year only | 50* | 11 | 0* | 0* | 0* | 126 | 176* | 0* |
| Proceeds from long-term debt | year only | year only | 0 | 0* | 0* | 0* | 489 | 0* | 0* |
| Repayments of long-term debt | year only | 238* | 4 | 4* | 4* | 5* | 333 | 0* | 0* |
| Net cash from financing activities | year only | 40* | (17) | (5)* | (3)* | (5)* | 7 | (173)* | 0* |
| Net change in cash | — | — | 53 | — | — | — | — | — | — |
| Net cash from operating activities | year only | — | — | — | — | — | — | — | — |
| Net cash from investing activities | year only | — | — | — | — | — | — | — | — |
| Net cash from financing activities | year only | — | — | — | — | — | — | — | — |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Indivior Pharmaceuticals | 305 | 356 | 97* | 118.0M | — | 10-QSep 30, 2026 |
| Apellis Pharmaceuticals | 405 | 268 | (61) | 128.0M | 6.6 quarters | 10-QMar 31, 2026 |
| Biocryst Pharmaceuticals | 155 | not reported | 104* | 255.5M | — | 10-QJun 30, 2026 |
| Agios Pharmaceuticals | 100 | 45 | (57)* | 59.7M | 10.8 quarters | 10-QJun 30, 2026 |
| Amicus Therapeutics | 214 | 185* | 16* | 314.0M | — | 10-KDec 31, 2025 |
| Supernus Pharmaceuticals | 176 | 227 | 6.6* | 58.2M | — | 10-QSep 30, 2026 |
| Sarepta Therapeutics | 571 | 401 | 197* | 105.6M | — | 10-QJun 30, 2026 |
| Bausch Health Companies | 2,485 | 2,941 | 814* | 374.3M | — | 10-QSep 30, 2026 |
| Recursion Pharmaceuticals | 550 | 19 | (77)* | 622.8M | 6.2 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.